Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Affimed ( (AFMD) ) has shared an announcement.
Affimed has reported promising results from its AFM24/atezolizumab combination therapy in heavily pretreated non-small cell lung cancer (NSCLC) patients. The treatment demonstrated significant clinical activity, with a 21% overall response rate in EGFR wild-type patients and a 24% rate in EGFR mutant patients. The company intends to advance the therapy by increasing the dosage to 720 mg weekly, following evidence that higher exposure improves response rates and survival outcomes.
More about Affimed
Affimed N.V. is a clinical-stage immuno-oncology company based in Mannheim, Germany. It focuses on leveraging the innate immune system to combat cancer, utilizing its proprietary ROCK® platform to create innate cell engagers (ICE®) that target and destroy tumor cells. The company’s product pipeline includes several ICE® molecules for treating hematologic and solid tumors.
YTD Price Performance: -65.92%
Average Trading Volume: 201,129
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $32.43M
For a thorough assessment of AFMD stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Microsoft Leads AI Race with Massive Nvidia GPU Purchases in 2024
- Nike Q2 Earnings Preview: Analysts Expect a Decline in Earnings and Sales
- Salesforce Hits 1,000 Agentforce Deals, Launches Agentforce 2.0
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
